12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin
NCT ID: NCT00473525
Last Updated: 2010-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
303 participants
INTERVENTIONAL
2007-07-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
NCT02554877
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
NCT04617275
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
NCT03538743
Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.
NCT02206607
Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants
NCT03796182
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Placebo QD
PF-00734200 10 mg QD
PF-00734200 10 mg QD
10 mg QD
PF-00734200 20 mg QD
PF-00734200 20 mg QD
20 mg QD
PF-00734200 5 mg QD
PF-00734200 5 mg QD
5 mg QD
PF-00734200 2 mg QD
PF-00734200 2 mg QD
2 mg QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo QD
PF-00734200 10 mg QD
10 mg QD
PF-00734200 20 mg QD
20 mg QD
PF-00734200 5 mg QD
5 mg QD
PF-00734200 2 mg QD
2 mg QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hb1AC \>7%-11% inclusive
* Male and females 18-70; females must be post-menopausal
* On a stable dose of metformin hydrochloride
Exclusion Criteria
* Women of childbearing potential, pregnant or nursing
* Evidence of diabetic complications with significant end-organ damage
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Jonesboro, Arkansas, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Carmichael, California, United States
Pfizer Investigational Site
Chula Vista, California, United States
Pfizer Investigational Site
Fair Oaks, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
National City, California, United States
Pfizer Investigational Site
Paramount, California, United States
Pfizer Investigational Site
Roseville, California, United States
Pfizer Investigational Site
Sacramento, California, United States
Pfizer Investigational Site
DeFuniak Springs, Florida, United States
Pfizer Investigational Site
Destin, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
New Port Richey, Florida, United States
Pfizer Investigational Site
New Port Richey, Florida, United States
Pfizer Investigational Site
Palm Harbor, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Conyers, Georgia, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Skokie, Illinois, United States
Pfizer Investigational Site
Skokie, Illinois, United States
Pfizer Investigational Site
Wheeling, Illinois, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
Pfizer Investigational Site
Brockton, Massachusetts, United States
Pfizer Investigational Site
Worcester, Massachusetts, United States
Pfizer Investigational Site
Ann Arbor, Michigan, United States
Pfizer Investigational Site
Canton, Michigan, United States
Pfizer Investigational Site
Flint, Michigan, United States
Pfizer Investigational Site
Biloxi, Mississippi, United States
Pfizer Investigational Site
Picayune, Mississippi, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Trenton, New Jersey, United States
Pfizer Investigational Site
Cary, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Marion, Ohio, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Carnegie, Pennsylvania, United States
Pfizer Investigational Site
East Providence, Rhode Island, United States
Pfizer Investigational Site
Bartlett, Tennessee, United States
Pfizer Investigational Site
Collierville, Tennessee, United States
Pfizer Investigational Site
Kingsport, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Irving, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Virginia Beach, Virginia, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Floridablanca, Santander Department, Colombia
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Giengen an der Brenz, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Santiago de Compostela, La Coruña, Spain
Pfizer Investigational Site
Alcalá de Henares, Madrid, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A7941005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.